Background The success of human papillomavirus (HPV) national immunization program
depends on effective strategies in optimizing the uptake of HPV vaccine. Given the …

Introduction The World Health Organization (WHO) recommends that human papillomavirus
(HPV) vaccination programs are established to be cost-effective before implementation …

Background Human papillomavirus (HPV) infection can have severe consequences both in
women and men. Preadolescent girls are vaccinated against HPV worldwide but a gender …

Abstract Introduction In the United States, routine human papillomavirus (HPV) vaccination
is recommended for females and males at age 11 or 12 years; the series can be started at …

A critical review of cost-effectiveness analyses of HPV vaccination in males was conducted
and nine studies were identified in different countries. Due to the heterogeneity among these …

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

Introduction: Many economic evaluations of HPV vaccination have been published, but most
have focused on the prevention of cervical disease as a primary health outcome. The cost …

Background: With promising efficacy results from randomized control trials of human
papillomavirus (HPV) vaccines and the availability of new screening paradigms …

Abstract Background and Objectives Giving the human papillomavirus (HPV) vaccination to
females has been shown to be cost-effective in most countries. The epidemiological …

Fifteen years following the approval of the first human papillomavirus (HPV) vaccine,
cervical cancer continues to be a significant source of morbidity and mortality among women …